Join the Oncology Voice Network. Join for Free
Why Companies Should Hire Aspiring MSLs (and How)
MSL role Medical Science Liaison aspiring MSLs networking in medical affairs diversity hiring in pharmaceuticals

Why Companies Should Hire Aspiring MSLs (and How)


Share This Article


Summary

In this episode, Alyson Evans joins Tom Caravela to discuss the evolving landscape of the MSL role. Alyson shares her career journey and offers insights on hiring practices, comparing the strengths of aspiring versus experienced MSLs. She provides comprehensive advice for those looking to break into the field, highlighting the importance of networking and purposeful diversity in hiring. Alyson also predicts future trends that could shape the MSL role. The episode wraps up with final thoughts and actionable advice for aspiring MSLs, encouraging listeners to remain proactive and engaged in their career development.

My guest today is Alyson Evans, Director, Medical Affairs with Sirtex Pharmaceuticals. Alyson discusses why companies should consider hiring aspiring MSLs.

She shares…

👉 Why she considers hiring aspiring MSLs and what her experience has been
👉 The advantages and disadvantages of hiring aspiring MSLs
👉 How to go about hiring aspiring MSLs
👉 What “purposeful diversity hiring” is
👉 What advice she has for aspiring MSLs looking to land a role as a Medical Science Liaison

Click for Source
MSL role, Medical Science Liaison, aspiring MSLs, networking in medical affairs, diversity hiring in pharmaceuticals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Explore OVN